Toolkit Developed for Diagnosis and Management of Menopause
|
By LabMedica International staff writers Posted on 04 Aug 2014 |
A simple toolkit designed to help general practitioners (GP) diagnose and manage menopause is now available free of charge.
Created at Monash University (VIC, Australia), the "Practitioner Toolkit for Managing the Menopause" is the world’s first such kit, designed for GPs to use with women from the age of 40. The research team, led by Prof. Susan Davis, combined existing research on menopause, diagnostic algorithms, and extensive clinical experience to develop the diagnostic tool. It also helps the GP work through a patient’s medical history and risk factors to arrive at an optimal solution.
The toolkit fills the void of clear guidelines on diagnosis and management, equipping primary-care physicians, as well as nurses, with the fundamentals to provide more effective care for women. “There are many detailed guidelines available on menopause but the reality is that most GPs don’t have the time to work through a 40 page report [...] with a patient,” said Prof. Davis, “Based on feedback from patients and doctors we realized there’s widespread confusion." Also, "With many recent medical graduates receiving little training in this area, we realized there was a clear need for simple and practical guidelines,” she added.
Menopausal symptoms vary widely from none at all to debilitating, making a straightforward diagnosis difficult. "Every woman has her own individual experience of menopause and that sometimes makes it tricky to diagnose," said Prof. Davis. The kit includes a flow chart of standardized questions for doctors to ask in a routine consultation to help identify women who may be entering menopause. The kit also flags safety concerns, provides a list of hormone therapies approved by regulators in different countries, and lists non-hormonal therapies that have evidence to support their use. It also helps inform on benefits and risks of menopausal treatments. The kit is designed to work as well for a woman of age 41 in Madras as for one of age 48 in Manhattan, and the International Menopause Society is promoting its global use, stating that it is the first to present structured practical advice.
Jane Elliott, MD, said the toolkit was clear and accessible, making it ideal to use in GP consultations. Dr. Anna Fenton, a leading endocrinologist and president of the Australasian Menopause Society, also welcomed and recommended the toolkit: “In an area fraught with myths and misinformation, this toolkit provides concise and accurate information. The key messages are clear and the advice is practical and evidence-based,” said Dr. Fenton.
The paper on the kit was published online July 6, 2014, in the journal Climacteric.
Related Links:
Monash University
Menopause Toolkit for GPs
Created at Monash University (VIC, Australia), the "Practitioner Toolkit for Managing the Menopause" is the world’s first such kit, designed for GPs to use with women from the age of 40. The research team, led by Prof. Susan Davis, combined existing research on menopause, diagnostic algorithms, and extensive clinical experience to develop the diagnostic tool. It also helps the GP work through a patient’s medical history and risk factors to arrive at an optimal solution.
The toolkit fills the void of clear guidelines on diagnosis and management, equipping primary-care physicians, as well as nurses, with the fundamentals to provide more effective care for women. “There are many detailed guidelines available on menopause but the reality is that most GPs don’t have the time to work through a 40 page report [...] with a patient,” said Prof. Davis, “Based on feedback from patients and doctors we realized there’s widespread confusion." Also, "With many recent medical graduates receiving little training in this area, we realized there was a clear need for simple and practical guidelines,” she added.
Menopausal symptoms vary widely from none at all to debilitating, making a straightforward diagnosis difficult. "Every woman has her own individual experience of menopause and that sometimes makes it tricky to diagnose," said Prof. Davis. The kit includes a flow chart of standardized questions for doctors to ask in a routine consultation to help identify women who may be entering menopause. The kit also flags safety concerns, provides a list of hormone therapies approved by regulators in different countries, and lists non-hormonal therapies that have evidence to support their use. It also helps inform on benefits and risks of menopausal treatments. The kit is designed to work as well for a woman of age 41 in Madras as for one of age 48 in Manhattan, and the International Menopause Society is promoting its global use, stating that it is the first to present structured practical advice.
Jane Elliott, MD, said the toolkit was clear and accessible, making it ideal to use in GP consultations. Dr. Anna Fenton, a leading endocrinologist and president of the Australasian Menopause Society, also welcomed and recommended the toolkit: “In an area fraught with myths and misinformation, this toolkit provides concise and accurate information. The key messages are clear and the advice is practical and evidence-based,” said Dr. Fenton.
The paper on the kit was published online July 6, 2014, in the journal Climacteric.
Related Links:
Monash University
Menopause Toolkit for GPs
Latest Clinical Chem. News
- Machine Learning Model Shows Promise for Improving Metanephrine Testing Accuracy
- Blood Test Enters UK Primary Care Pathway for Earlier Alzheimer’s Diagnosis
- Common HbA1c Assay May Miss Diabetes in People with Sickle Cell Trait
- Blood Protein Panel Predicts Timing of ALS Symptom Onset
- Siemens Adds CE-Marked Capillary Claims for 24 Assays on Atellica Analyzers
- Preoperative Blood Test Predicts Colorectal Cancer Recurrence and Metastasis
- New Machine-Learning Equation Improves LDL Cholesterol Assessment
- Ultrasensitive Biosensor Detects Early Liver Fibrosis from Blood
- Blood Biomarker May Signal Cognitive Decline Risk a Decade Before Symptoms
- Blood Test Improves Alzheimer’s Diagnosis Across Care Settings
- New Immunoassay Enables Ultrasensitive Blood-Based Tau Tangle Measurement
- Blood Hormone Pattern Distinguishes Endometriosis with High Accuracy
- Blood Test Brings Alzheimer’s Biomarker Assessment to Routine Labs
- Alzheimer’s Biomarkers Identify Faster Cognitive Decline in Adults Over 80
- ADLM Issues Laboratory Guidance for Gender-Diverse Patient Care
- FDA-Approved Test Identifies Low Risk of Large Esophageal Varices in Cirrhosis
Channels
Molecular Diagnostics
view channel
AI Tool Improves Long-Read Detection of Cancer Mutations
Accurate identification of somatic mutations remains difficult, particularly in structurally complex genomic regions. Short-read sequencing pipelines can miss clinically relevant variants, limiting research... Read more
FDA Clears Molecular Test for Bacterial Vaginosis and Candida Vaginitis
Vaginitis is a common reason for clinical visits, with bacterial vaginosis and Candida vaginitis among the leading causes. Overlapping symptoms and reliance on microscopy, pH testing, and clinical observation... Read moreHematology
view channel
Age-Specific CBC Reference Intervals Support Pediatric Diagnosis in Vietnam
Complete blood count (CBC) results underpin pediatric evaluation for anemia, infection, inflammation, and platelet disorders. Yet laboratories in Vietnam have largely relied on reference intervals derived... Read more
Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
Minimal residual disease (MRD) monitoring is pivotal in multiple myeloma, where persistent malignant plasma cells drive relapse risk and help guide therapy decisions. In the United States, approximately... Read moreImmunology
view channel
Study Reveals Immune Mechanism Driving Severe COVID-19 Progression
Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read moreMicrobiology
view channel
New Sensitive Blood Assay Detects Tuberculosis Antigen Directly in Blood
Tuberculosis continues to be a leading global infectious disease, and diagnosis still hinges on sputum samples that many patients cannot produce early in illness. Delays in confirming Mycobacterium tuberculosis... Read more
High-Throughput Automated Platform to Advance Latent Tuberculosis Testing
Testing for tuberculosis remains a persistent global need, with demand driven by immigration screening, pre-treatment evaluation for immunosuppressive therapies, and public health programs.... Read morePathology
view channel
AI Pathology Tool Predicts Relapse Risk in Stage II Colorectal Cancer
Bowel cancer is Australia’s fourth most commonly diagnosed cancer and the second leading cause of cancer death, while remaining the third most common cancer worldwide. In stage-two disease, determining... Read more
AI Pathology Tool Stratifies Rectal Cancer to Guide Chemoradiotherapy
Choosing intensified regimens for locally advanced rectal cancer is challenging because these therapies can cause serious side effects. Colorectal cancer is the fourth-most fatal cancer in the UK, and... Read more
PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read moreTechnology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channelLumiQuick Advances Oxidative Stress Research with Expanded AOXRE Portfolio
LumiQuick Diagnostics, Inc. (Santa Clara, CA, USA) has announced the addition of the AOXRE product line to its portfolio and introduced expanded services to help biotechnology and diagnostic companies... Read more
Collaboration Advances Sputum-Based Diagnostics for Asthma and COPD
Asthma and chronic obstructive pulmonary disease are highly prevalent inflammatory airway conditions, affecting more than 40 million Americans and more than 650 million people worldwide.... Read more








